A better understanding of the cis-acting regulatory elements and corresponding trans-acting factors that promote or suppress FV-short splicing may point out new therapeutic targets for the downregulation of FV-short expression in TFPIα-dependent bleeding disorders. Here, F5 is linked to hemorrhagic disease.